ロード中...
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
INTRODUCTION: Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of...
保存先:
| 出版年: | BMJ Open |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7045211/ https://ncbi.nlm.nih.gov/pubmed/31988233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-033667 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|